Anal Neoplasms

  • Brian R. KannEmail author


While anal neoplasms account for less than 5% of lower gastrointestinal tract malignancies and less than 1% of new malignancies overall in the United States, knowledge regarding the diagnosis and management of these lesions is critical to the practice of colon and rectal surgery. It is estimated that there will be 8200 new cases of anal cancer diagnosed in 2017, and an estimated 1100 deaths; both of these represent a continued slow upward trend in recent years. This chapter will outline the diagnosis and management of anal neoplasms, both malignant and pre-malignant.


Anal neoplasms Squamous cell carcinoma Adenocarcinoma Melanoma Paget’s disease GIST Bowen’s disease Anal margin basal cell cancer 


  1. 1.
    Simpson JAD, Scholefield JH. Diagnosis and management of anal intraepithelial neoplasia and anal cancer. BMJ. 2011;343:d6818.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Pineda CE, Welton ML. Management of anal squamous intraepithelial lesions. Clin Colon Rectal Surg. 2009;22:94–101.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Chin JY, Hong TS, Wo JY. Anal cancer: current and future treatment strategies. Gastrointest Cancer Targets Ther. 2013;3:19–27.Google Scholar
  5. 5.
    Shridhar R, Shibata D, Chan E, Thomas CR. Anal cancer: current standards in care and recent changes in practice. CA Cancer J Clin. 2015;65:139–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Daling JR, Madeleine MM, Johnson LG, et al. Human papilloma virus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Shiels MS, Pfeiffer RM, Chaturvedi AK, et al. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst. 2012;104:1591–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342:782–800.Google Scholar
  9. 9.
    Osborne MC, Maykel J, Johnson EK, Steele SR. Anal squamous cell carcinoma: an evolution in disease and management. World J Gastroenterol. 2014;20:13052–9.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Tanum G, Tveit K, Karlsen KO. Diagnosis of anal carcinoma – doctor’s finger still the best. Oncology. 1991;48:383–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Samdani T, Nash GM. Anal cancer. In: Steele SR, Hull TL, Read TE, et al., editors. The ASCRS textbook of colon and rectal surgery. 3rd ed. Cham: Springer; 2016. p. 357–71.CrossRefGoogle Scholar
  12. 12.
    Billingham R. Neoplasms of the anus and the perianal skin. In: Mazier WP, Levien DH, Luchtefeld MA, Senegore AJ, editors. Surgery of the colon, rectum, and anus. Philadelphia: WB Saunders; 1995. p. 205–28.Google Scholar
  13. 13.
    NCCN clinical practice guidelines in oncology – anal carcinoma (version 1.2017 – November 23, 2016). Available from: Accessed March 23, 2017.
  14. 14.
    Bilimoria KY, Bentrem DJ, Rock CE, et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009;52:624–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Kolev NY, Tonev AY, Ignatov VL, et al. The role of 3-D endorectal ultrasound in rectal cancer: our experience. Int Surg. 2014;99:106–11.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Granata V, Fusco R, Reginelli A, et al. Radiological assessment of anal cancer: an overview and update. Infect Agent Cancer. 2016;11:52.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Granata V, Fusco R, Catalano O, et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: the role of intravoxel incoherent motion in diffusion-weighted imaging. PLoS ONE. 2015;10:e0142876.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:720–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Ed W, Heriot AG, Ng M, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer. 2009;100:693–700.CrossRefGoogle Scholar
  20. 20.
    Bhuva NJ, Glynne-Jones R, Sonoda L, et al. To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol. 2012;23:2078–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Caldarella C, Annunziata S, Treglia G, et al. Diagnostic performance of positron emission tomography /computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal cancer: a systematic review and meta-analysis. Sci World J. 2014;2014:196068.CrossRefGoogle Scholar
  22. 22.
    Mistrangelo M, Pelosi E, Bellò M, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys. 2012;84:66–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Wells IT, Fox BM. PET/CT in anal cancer – is it worth doing? Clin Radiol. 2012;67:535–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Jones M, Hruby G, Solomon M, et al. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17:310–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Buroker TR, Nigro NM, Bradley G, et al. Combined therapy for cancer of the anal canal: a follow-up report. Dis Colon Rectum. 1977;20:677–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Nigro ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Nigro ND. Multidisciplinary management of cancer of the anus. World J Surg. 1987;11:446–51.PubMedCrossRefGoogle Scholar
  29. 29.
    UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet. 1996;348:1049–54.CrossRefGoogle Scholar
  30. 30.
    Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.PubMedCrossRefGoogle Scholar
  33. 33.
    Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.PubMedCrossRefGoogle Scholar
  34. 34.
    James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation for treatment of squamous-cell carcinoma of the anus (ACT II): randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal carcinoma: final analysis of the randomised UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Rothenstein DA, Dasgupta T, Chou JF, et al. Comparison of outcomes of intensity-modulated radiotherapy and 3-D conformal radiotherapy for anal squamous cell carcinoma using a propensity score analysis. J Clin Oncol. 2011;29:2011.CrossRefGoogle Scholar
  37. 37.
    Yates A, Carroll S, Kneebone A, et al. Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. Clin Oncol. 2015;27:700–7.CrossRefGoogle Scholar
  38. 38.
    Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010;10:189.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Deutsch E, Lemanski C, Pignon JP, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013;24:2834–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kochhar R, Renehan AG, Mullan D, et al. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. Eur Radiol. 2017;27:607–17.PubMedCrossRefGoogle Scholar
  41. 41.
    Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Color Dis. 2011;26:201–10.CrossRefGoogle Scholar
  42. 42.
    Teagle AR, Gilbert DC, Jones JR, et al. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer. Nucl Med Commun. 2016;37:1038–45.PubMedCrossRefGoogle Scholar
  43. 43.
    Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Color Dis. 2006;8:124–9.CrossRefGoogle Scholar
  44. 44.
    Van der Wal BC, Cleffken BI, Gulec B, et al. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg. 2001;5:383–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Ghouti L, Houvenaeghel G, Moutardier V, et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum. 2005;48:16–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Butler CE, Gündeslioglu AO, Rodriguez-Bigas MA. Outcomes of immediate rectus abdominus myocutaneous flap for reconstruction for irradiated abdominoperineal resection defects. J Am Coll Surg. 2008;206:694–703.PubMedCrossRefGoogle Scholar
  47. 47.
    Hinojosa MW, Parikh DA, Menon R, et al. Recent experience with abdominal perineal resection with vertical rectus abdominus myocutaneous flap reconstruction after preoperative pelvic radiation. Am Surg. 2009;75:995–9.PubMedGoogle Scholar
  48. 48.
    Chessin DB, Hartley J, Cohen AM, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12:104–10.PubMedCrossRefGoogle Scholar
  49. 49.
    Devulapalli C, Jia Wei AT, DiBiagio JR, et al. Primary versus flap closure of perineal defects following oncologic resection: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137:1602–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh M, Kinsley S, Huang A, et al. Gracilis flap reconstruction of the perineum: an outcomes analysis. J Am Coll Surg. 2016;223:602–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Das P, Cantor SB, Parker CL, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010;116:822–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Joseph K, Vos LJ, Warkentin H, et al. Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer. Radiother Oncol. 2016;120:228–33.PubMedCrossRefGoogle Scholar
  53. 53.
    Sunesen KG, Nørgaard M, Lundby L, et al. Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for anal cancer: a Danish multicenter cross-sectional questionnaire study. Color Dis. 2015;17:O230–9.CrossRefGoogle Scholar
  54. 54.
    Bentzen AG, Balteskard L, Wanderàs EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013;52:736–44.PubMedCrossRefGoogle Scholar
  55. 55.
    Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500–10.PubMedCrossRefGoogle Scholar
  56. 56.
    Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systemic review and meta-analysis. Lancet Oncol. 2012;13:487–500.PubMedCrossRefGoogle Scholar
  57. 57.
    Chang GJ, Gonzales RJ, Skibber JM, et al. A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon Rectum. 2009;52:1375–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Bertelson N, Blumetti J, Cintron J, et al. Anal adenocarcinoma: outcomes in an uncommon malignancy. Am Surg. 2015;81:1114–7.PubMedGoogle Scholar
  59. 59.
    Chang AE, Kernell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664–78.PubMedCrossRefGoogle Scholar
  60. 60.
    Parra RS, de Almeida ALNR, Badiale GB, et al. Melanoma of the anal canal. Clinics. 2010;65:1063–5.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Zhong J, Zhou JN, Xu FP, Shang JQ. Diagnosis and treatment of anorectal malignant melanoma: a report of 22 cases with literature review. Ai Zheng. 2006;25:619–24.PubMedGoogle Scholar
  62. 62.
    Garrett K, Kalady MF. Anal neoplasms. Surg Clin North Am. 2010;90:147–61.PubMedCrossRefGoogle Scholar
  63. 63.
    Chen H, Cai Y, Liu Y, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis. Medicine. 2016;95:e2770.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64 year experience at Memorial Sloan Kettering Cancer Center. Dis Colon Rectum. 1995;38:146–51.PubMedCrossRefGoogle Scholar
  65. 65.
    Podnos YD, Tsai NC, Smith D, Ellenhorn JD. Factors affecting survival in patients with anal melanoma. Am Surg. 2006;72:917–20.PubMedGoogle Scholar
  66. 66.
    Kiran RP, Rottoli M, Pokala N, Fazio VW. Long-term outcomes after local excision and radical surgery for anal melanoma: data from a population database. Dis Colon Rectum. 2010;53:402–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Metildi C, McLemore EC, Tran T, et al. Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry. Am Surg. 2013;79:1068–74.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10:81–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Darier J, Coulillaud P. Concerning a case of Paget disease of the perineal and scrotal area. Ann Dermatol Syphiligr. 1893;4:25–33.Google Scholar
  70. 70.
    Kyriazanos ID, Stamos NP, Miliadis L, et al. Extra-mammary Paget’s disease of the perianal region: a review of the literature emphasizing the operative management technique. Surg Oncol. 2011;20:e61–71.PubMedCrossRefGoogle Scholar
  71. 71.
    Berardi RS, Lee S, Chen HP. Perianal extramammary Paget’s disease. Surg Gynecol Obstet. 1988;167:359–66.PubMedGoogle Scholar
  72. 72.
    Banerjee S, Chatterjee M, Chand K. Extramammary Paget’s disease. Indian J Dermatol Venereol Leprol. 2005;71:417–20.PubMedCrossRefGoogle Scholar
  73. 73.
    Sahai A, Kodner IJ. Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg. 2006;19:88–93.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Beck DE, Fazio VW. Perianal Paget’s disease. Dis Colon Rectum. 1987;30:263–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Perez DR, Trakarnsanga A, Shia J, et al. Management and outcome of perianal Paget’s disease: a 6-decade institutional experience. Dis Colon Rectum. 2014;57:747–51.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Murakami K, Tanimura H, Ishimoto K, et al. Reconstruction with bilateral gluteus maximus rotation flap after wide local excision for perianal extramammary Paget’s disease. Report of two cases. Dis Colon Rectum. 1996;39:227–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Gaertner WB, Hagerman GF, Goldberg SM, Finne CO. Perianal Paget’s disease treated with wide excision and gluteal flap reconstruction: report of a case and review of the literature. Dis Colon Rectum. 2008;51:1842–5.PubMedCrossRefGoogle Scholar
  78. 78.
    St Peter SD, Pera M, Smith AA, et al. Wide local excision and split-thickness skin graft for circumferential Paget’s disease of the anus. Am J Surg. 2004;187:413–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Marchesa P, Fazio VW, Oliart S, et al. Long-term outcome of patients with perianal Paget’s disease. Ann Surg Oncol. 1997;4:475–80.PubMedCrossRefGoogle Scholar
  80. 80.
    McCarter MD, Quan SH, Busam K, et al. Long-term outcome of perianal Paget’s disease. Dis Colon Rectum. 2003;46:612–6.PubMedCrossRefGoogle Scholar
  81. 81.
    Isik O, Aytac E, Brainard J, et al. Perianal Paget’s disease: three decades experience of a single institution. Int J Color Dis. 2016;31:29–34.CrossRefGoogle Scholar
  82. 82.
    Sarmiento JM, Wolff BG, Burgart LJ, et al. Paget’s disease of the perianal region – an aggressive disease? Dis Colon Rectum. 1997;40:1187–94.PubMedCrossRefGoogle Scholar
  83. 83.
    Conklin A, Hassan I, Chua HK, et al. Long-term functional and quality of life outcomes of patients after repair of large perianal skin defects for Paget’s and Bowen’s disease. J Gastrointest Surg. 2009;13:951–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Mirer E, El Syaed F, Ammoury A, et al. Treatment of mammary and extramammary Paget’s skin disease with topical imiquimod. J Dermatolog Treat. 2006;17:167–71.PubMedCrossRefGoogle Scholar
  85. 85.
    Vereecken P, Awada A, Ghanem G, et al. A therapeutic approach to perianal Paget’s disease: topical imiquimod can be useful to prevent or defer surgery. Med Sci Monit. 2007;13:CS75–7.PubMedGoogle Scholar
  86. 86.
    Velenik V, Segedin B, Anderluh F, et al. Radiotherapy for perianal Paget’s disease: a case report. Tumori. 2008;94:750–3.PubMedCrossRefGoogle Scholar
  87. 87.
    Hata M, Omura M, Koike I, et al. Role of radiotherapy as curative treatment of extramammary Paget’s disease. Int J Radiat Oncol Biol Phys. 2011;80:47–54.PubMedCrossRefGoogle Scholar
  88. 88.
    Yasar B, Yasar S, Gunes P. Extramammary Paget’s disease of the perianal region treated successfully with radiotherapy. Int J Color Dis. 2015;30:711–2.CrossRefGoogle Scholar
  89. 89.
    Runfola MA, Weber TK, Rodriguez-Bigas MA, et al. Photodynamic therapy for residual neoplasms of the perianal skin. Dis Colon Rectum. 2000;43:499–502.PubMedCrossRefGoogle Scholar
  90. 90.
    Bowen JT. Precancerous dermatoses: a study of 2 cases of chronic atypical epithelial proliferation. J Cutan Dis. 1912;30:241–55.Google Scholar
  91. 91.
    Vickers PM, Jackman RJ, McDonald JR. Anal carcinoma in situ: report of three cases. South Surg. 1939;8:503–7.Google Scholar
  92. 92.
    Cleary RK, Schaldenbrand JD, Fowler JJ, et al. Perianal Bowen’s disease and anal intraepithelial neoplasia: review of the literature. Dis Colon Rectum. 1999;42:945–51.PubMedCrossRefGoogle Scholar
  93. 93.
    Margenthaler JA, Dietz DW, Mutch MG, et al. Outcomes, risk of other malignancies, and need for formal mapping procedures in patients with perianal Bowen’s disease. Dis Colon Rectum. 2004;47:1655–60. discussion 1660-1PubMedCrossRefGoogle Scholar
  94. 94.
    Beck DE, Fazio VW, Jagelman DG, Lavery IC. Perianal Bowen’s disease. Dis Colon Rectum. 1988;31:419–22.PubMedCrossRefGoogle Scholar
  95. 95.
    Marchesa P, Fazio VW, Oliart S, et al. Perianal Bowen’s disease: a clinicopathologic study of 47 patients. Dis Colon Rectum. 1997;40:1286–93.PubMedCrossRefGoogle Scholar
  96. 96.
    Sarmiento JM, Wolff BG, Burgart LJ, et al. Perianal Bowen’s disease: associated tumors, human papillomavirus, surgery, and other controversies. Dis Colon Rectum. 1997;40:912–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Graham BD, Jetmore AB, Foote JE, Arnold LK. Topical 5-fluorouracil in the management of extensive anal Bowen’s disease: a preferred approach. Dis Colon Rectum. 2005;48:444–50.PubMedCrossRefGoogle Scholar
  98. 98.
    Welch ML, Grabski WJ, McCollough ML, et al. 5-fluorouracil iontophoretic therapy for Bowen’s disease. J Am Acad Dermatol. 1997;36(6 Pt 1):956–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Newlin HE, Zlotecki RA, Morris CG, et al. Squamous cell carcinoma of the anal margin. J Surg Oncol. 2004;86:55–62.PubMedCrossRefGoogle Scholar
  100. 100.
    Nielsen OV, Jensen SL. Basal cell carcinoma of the anus – a clinical study of 34 cases. Br J Surg. 1981;68:856–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Paterson CA, Young-Fadok TM, Dozois RR. Basal cell carcinoma of the perianal region: 20-year experience. Dis Colon Rectum. 1999;42:1200–2.PubMedCrossRefGoogle Scholar
  102. 102.
    Gibson GE, Ahmed I. Perianal and genital basal cell carcinoma: a clinicopathologic review of 51 cases. J Am Acad Dermatol. 2001;45:68–71.PubMedCrossRefGoogle Scholar
  103. 103.
  104. 104.
    Edge SB, Byrd DB, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Colon and Rectal SurgeryOchsner Medical CenterNew OrleansUSA

Personalised recommendations